Alexion Announces Settlement On Eculizumab Patent; $66.4 Million In Sales For Soliris
This article was originally published in The Pink Sheet Daily
Executive Summary
The single-product company will pay Oklahoma Medical Research Foundation $10 million, ending a patent-infringement suit.
You may also be interested in...
EMEA Grants First Positive Opinion Under Accelerated Assessment To Soliris
Alexion’s treatment for a rare blood disease met CHMP’s criteria for accelerated review.
Alexion Biologic Soliris Is First To Get FDA Nod For Rare Blood Disease
Soliris is slated to launch within two weeks from its March 16 approval.
Alexion/P&G Pexelizumab Failed Phase III Could Compromise Development Partnership
The APEX-AMI study of pexelizumab in patients with acute myocardial infarction failed to meet its endpoint of reduction in mortality.